TD Cowen Maintains Buy on Vera Therapeutics, Raises Price Target to $78

Benzinga Newsdesk www.benzinga.com Positive 82.0%

Neg 0% Neu 0% Pos 82%

TD Cowen analyst Ritu Baral maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and raises the price target from $73 to $78.